Vitamin D: Actions for the new millennium.

作者: Harbans Lai , Rajesh Pandey , S. K. Aggarwal

DOI: 10.1007/BF02867555

关键词:

摘要: The past two decades have witnessed new facets in vitamin D metabolism. Free D3 till now considered to be limited animal sources, has been shown occur plants. Further, the extrarenal synthesis of active or calcitriol documented physiological as well certain pathological conditions. At cellular level, acts through a dual mechanism. genomic pathway involves receptor (VDR) which is ubiquitous distribution and linked with various diseases. Besides, nongenomic VDR—independent also exists. biological effects can no longer dismissed by merely referring calcium/bone homeostasis. It enhances perinatal growth suppresses abnormal growth, well. on endocrine, immune, cardiovascular, reproductive nervous systems characterized. compelling believe that and/or its analogues will find extensive applications at least treatment osteoporosis, retardation, neoplasia, psoriasis, insulin resistance transplantation.

参考文章(74)
Young Ew, Oshima T, Systemic and cellular calcium metabolism and hypertension. Seminars in Nephrology. ,vol. 15, pp. 496- 503 ,(1995)
Joan M. O'Brien, Dennis M. Marcus, Daniel M. Albert, Jeffrey P. Gallo, The antineoplastic effect of vitamin D in transgenic mice with retinoblastoma. Investigative Ophthalmology & Visual Science. ,vol. 33, pp. 2354- 2364 ,(1992)
Stephen M. Krane, Louis V. Avioli, Metabolic bone disease Academic Press. ,(1977)
Daniel D. Bikle, Anita V. Ratnam, Cheryl D. Love-Schimenti, David F. C. Gibson, Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. Cancer Research. ,vol. 56, pp. 2789- 2794 ,(1996)
Venkateswara R. Naraparaju, Nobuto Yamamoto, Sucha O. Asbell, Deglycosylation of Serum Vitamin D3-binding Protein Leads to Immunosuppression in Cancer Patients Cancer Research. ,vol. 56, pp. 2827- 2831 ,(1996)
Mark R Haussler, U. Berger, J. W. Pike, R. A. McClelland, R. C. Coombes, P. Wilson, K. Colston, Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Research. ,vol. 47, pp. 6793- 6799 ,(1987)
Mario A. Anzano, Christopher W. Peer, Mark W. Shrader, Milan R. Uskoković, Anita B. Roberts, Larry T. Mullen, Michael B. Sporn, Daniel L. Logsdon, Marta C. Welsh, John J. Letterio, Charles C. Brown, Craig L. Driver, Joseph M. Smith, 1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a New Deltanoid (Vitamin D Analogue) for Prevention of Breast Cancer in the Rat Cancer Research. ,vol. 54, pp. 1653- 1656 ,(1994)
John A. Eisman, Robert L. Sutherland, Masafumi Koga, Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells. Cancer Research. ,vol. 48, pp. 2734- 2739 ,(1988)
Donna M. Peehl, Thomas A. Stamey, David Feldman, Roman J. Skowronski, Gordon K. Leung, Stephen T. Wong, Antiproliferative Effects of 1,25-Dihydroxyvitamin D3 on Primary Cultures of Human Prostatic Cells Cancer Research. ,vol. 54, pp. 805- 810 ,(1994)
Sylvia CHRISTAKOS, Mihali RAVAL-PANDYA, Roman P. WERNYJ, Wen YANG, Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3 Biochemical Journal. ,vol. 316, pp. 361- 371 ,(1996) , 10.1042/BJ3160361